Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.59 |
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 4/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15426812 | 0.85 | MAPT (0.55) | SMN1; SMN2MAPTKDM4ECYP1A2GLA | |
| SCHEMBL6239095 | 0.83 | MAPT (0.54) | SMN1; SMN2MAPTKDM4ECYP1A2GLA | |
| SCHEMBL11539971 | 0.82 | SMN1; SMN2 (0.56) | SMN1; SMN2MAPTCYP1A2CYP3A4GAA | |
| SCHEMBL7012446 | 0.82 | HSP90AA1 (0.54) | SMN1; SMN2MAPTKDM4ECYP1A2CYP3A4 | |
| SCHEMBL874798 | 0.81 | MAPT (0.53) | SMN1; SMN2MAPTKDM4ECYP1A2GLA | |
| SCHEMBL15549840 | 0.81 | HSD17B10 (0.57) | SMN1; SMN2MAPTKDM4ECYP1A2GLA | |
| SCHEMBL3112575 | 0.81 | MAPT (0.53) | SMN1; SMN2MAPTKDM4ECYP1A2GLA | |
| SCHEMBL6764561 | 0.81 | FFAR1 (0.61) | SMN1; SMN2MAPTKDM4ECYP1A2GLA | |
| SCHEMBL7049482 | 0.81 | SMN1; SMN2 (0.54) | SMN1; SMN2MAPTCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL7667895 | 0.80 | MAPT (0.51) | SMN1; SMN2MAPTKDM4ECYP1A2GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250114345-A1 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | ONCOPIA THERAPEUTICS, INC. D/B/A/ SK LIFE SCIENCE LABS | 2025-04-10 | — | — | US | disclosed |
| WO-2025049994-A1 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | ONCOPIA THERAPEUTICS, INC. D/B/A SK LIFE SCIENCE LABS (US) | 2025-03-06 | — | — | WO | disclosed |
| US-20250026742-A1 | COMPOUND AS ATR KINASE INHIBITOR | SUZHOU ARK BIOPHARMACEUTICAL CO., LTD. (CN) | 2025-01-23 | — | — | US | disclosed |
| CN-117794924-A | Compounds useful as inhibitors of ATR kinase | 苏州爱科百发生物医药技术有限公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-115703768-A | Compounds useful as inhibitors of ATR kinase | 苏州爱科百发生物医药技术有限公司 | 2023-02-17 | — | — | CN | disclosed |
| WO-2023016525-A1 | COMPOUND AS ATR KINASE INHIBITOR | 苏州爱科百发生物医药技术有限公司 | 2023-02-16 | — | — | WO | disclosed |
| WO-2023016525-A1 | COMPOUND AS ATR KINASE INHIBITOR | 苏州爱科百发生物医药技术有限公司 | 2023-02-16 | — | — | WO | disclosed |
| CN-105189508-B | Naphthenic base nitrile Pyrazolopyridine ketone as JANUS kinase inhibitor | 默沙东公司 | 2018-11-23 | — | — | CN | disclosed |
| US-10059705-B2 | Acyclic cyanoethylpyrazolo pyridones as janus kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-08-28 | — | — | US | disclosed |
| EP-2976340-B1 | CYCLOALKYL NITRILE PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2018-06-13 | — | — | EP | disclosed |
| US-20100069629-A1 | PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-03-18 | — | — | US | disclosed |
| CN-101547908-A | Heterocyclic derived metalloprotease inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2009-09-30 | — | — | CN | disclosed |
| EP-2089365-A1 | HETEROCYCLIC DERIVED METALLOPROTEASE INHIBITORS | Janssen Pharmaceutica, N.V. (BE) | 2009-08-19 | — | — | EP | disclosed |
| EP-2050749-A1 | PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-04-22 | — | — | EP | disclosed |
| US-7414063-B2 | Inhibitors of Akt (protein kinase B) | ELI LILLY AND COMPANY (US) | 2008-08-19 | — | — | US | disclosed |
| US-20080103129-A1 | HETEROCYCLIC DERIVED METALLOPROTEASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-05-01 | — | — | US | disclosed |
| WO-2008045668-A1 | HETEROCYCLIC DERIVED METALLOPROTEASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-04-17 | — | — | WO | disclosed |
| US-20070043040-A1 | Inhibitors of akt (protein kinase b) | ELI LILLY AND COMPANY | 2007-02-22 | — | — | US | disclosed |
| EP-1611105-A1 | ISOQUINOLINE-5-SULFONIC ACID AMIDES AS INHIBITORS OF AKT (PROTEIN KINASE B) | ELI LILLY AND COMPANY (US) | 2006-01-04 | — | — | EP | disclosed |
| WO-2004094386-A1 | ISOQUINOLINE-5-SULFONIC ACID AMIDES AS INHIBITORS OF AKT (PROTEIN KINASE B) | ELI LILLY AND COMPANY (US) | 2004-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250026742-A1 | COMPOUND AS ATR KINASE INHIBITOR | ATR, CHEK2, CHEK1 | SMN1; SMN2 2270/4885MAPT 1987/4885KDM4E 2567/4885 |
| US-20070043040-A1 | Inhibitors of akt (protein kinase b) | AKT1, AKT2, BRAF | SMN1; SMN2 2866/4885MAPT 3017/4885KDM4E 3055/4885 |
| US-20100069629-A1 | PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF | PIK3CA, AKT3, AKT1 | SMN1; SMN2 3098/4885MAPT 4385/4885KDM4E 2852/4885 |
| US-20080103129-A1 | HETEROCYCLIC DERIVED METALLOPROTEASE INHIBITORS | ADAM17, MMP25, ADAM33 | SMN1; SMN2 1626/4885MAPT 3836/4885KDM4E 1117/4885 |
| US-20250114345-A1 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | EP300, CREBBP, HDAC1 | SMN1; SMN2 3372/4885MAPT 1252/4885KDM4E 200/4885 |
| US-10059705-B2 | Acyclic cyanoethylpyrazolo pyridones as janus kinase inhibitors | JAK1, JAK2, JAK3 | SMN1; SMN2 4833/4885MAPT 4429/4885KDM4E 466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.